<?xml version='1.0' encoding='utf-8'?>
<document id="15917146"><sentence text="Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat."><entity charOffset="0-13" id="DDI-PubMed.15917146.s1.e0" text="Flunitrazepam" /><entity charOffset="54-67" id="DDI-PubMed.15917146.s1.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.15917146.s1.e0" e2="DDI-PubMed.15917146.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15917146.s1.e0" e2="DDI-PubMed.15917146.s1.e1" /></sentence><sentence text="Deaths have been reported among heroin addicts related to combined buprenorphine and flunitrazepam use"><entity charOffset="67-80" id="DDI-PubMed.15917146.s2.e0" text="buprenorphine" /><entity charOffset="85-98" id="DDI-PubMed.15917146.s2.e1" text="flunitrazepam" /><pair ddi="false" e1="DDI-PubMed.15917146.s2.e0" e2="DDI-PubMed.15917146.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15917146.s2.e0" e2="DDI-PubMed.15917146.s2.e1" /></sentence><sentence text=" The aim of this study was to determine the existence of a drug-drug interaction during the distribution phase of buprenorphine"><entity charOffset="114-127" id="DDI-PubMed.15917146.s3.e0" text="buprenorphine" /></sentence><sentence text=" Arterial blood gases were measured after intravenous administration of buprenorphine alone (30 mg/kg), flunitrazepam alone (40 mg/kg) or both drugs in rats"><entity charOffset="72-85" id="DDI-PubMed.15917146.s4.e0" text="buprenorphine" /><entity charOffset="104-117" id="DDI-PubMed.15917146.s4.e1" text="flunitrazepam" /><pair ddi="false" e1="DDI-PubMed.15917146.s4.e0" e2="DDI-PubMed.15917146.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15917146.s4.e0" e2="DDI-PubMed.15917146.s4.e1" /></sentence><sentence text=" Buprenorphine kinetics was studied in plasma and in striatum using cerebral microdialysis, both alone and after rat pretreatment with flunitrazepam"><entity charOffset="1-14" id="DDI-PubMed.15917146.s5.e0" text="Buprenorphine" /><entity charOffset="135-148" id="DDI-PubMed.15917146.s5.e1" text="flunitrazepam" /><pair ddi="false" e1="DDI-PubMed.15917146.s5.e0" e2="DDI-PubMed.15917146.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15917146.s5.e0" e2="DDI-PubMed.15917146.s5.e1" /></sentence><sentence text=" In contrast to buprenorphine or flunitrazepam alone, buprenorphine in combination with flunitrazepam induced a significant, rapid and sustained respiratory depression"><entity charOffset="16-29" id="DDI-PubMed.15917146.s6.e0" text="buprenorphine" /><entity charOffset="33-46" id="DDI-PubMed.15917146.s6.e1" text="flunitrazepam" /><entity charOffset="54-67" id="DDI-PubMed.15917146.s6.e2" text="buprenorphine" /><entity charOffset="88-101" id="DDI-PubMed.15917146.s6.e3" text="flunitrazepam" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e0" e2="DDI-PubMed.15917146.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e0" e2="DDI-PubMed.15917146.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e0" e2="DDI-PubMed.15917146.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e0" e2="DDI-PubMed.15917146.s6.e3" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e1" e2="DDI-PubMed.15917146.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e1" e2="DDI-PubMed.15917146.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e1" e2="DDI-PubMed.15917146.s6.e3" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e2" e2="DDI-PubMed.15917146.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15917146.s6.e2" e2="DDI-PubMed.15917146.s6.e3" /></sentence><sentence text=" Arterial PCO2 was increased at 1"><entity charOffset="10-14" id="DDI-PubMed.15917146.s7.e0" text="PCO2" /></sentence><sentence text="5 min (6" /><sentence text="7+/-0" /><sentence text="2 versus 5" /><sentence text="4+/-0" /><sentence text="3 and 5" /><sentence text="5+/-0" /><sentence text="3 kPa, respectively, P=0" /><sentence text="04) (mean+/-S" /><sentence text="E" /><sentence text="M" /><sentence text="), and arterial pH decreased (7" /><sentence text="37+/-0" /><sentence text="02 versus 7" /><sentence text="45+/-0" /><sentence text="02 and 7" /><sentence text="45+/-0" /><sentence text="01, respectively, P=0" /><sentence text="03)" /><sentence text=" Plasma buprenorphine kinetics was well described by a three-compartment linear model, with a distribution half-life of 7"><entity charOffset="8-21" id="DDI-PubMed.15917146.s26.e0" text="buprenorphine" /></sentence><sentence text="4+/-2" /><sentence text="7 min and an elimination half-life of 463" /><sentence text="9+/-152" /><sentence text="3 min" /><sentence text=" However, neither plasma nor striatal buprenorphine kinetics were significantly altered by pre-administration of flunitrazepam"><entity charOffset="38-51" id="DDI-PubMed.15917146.s31.e0" text="buprenorphine" /><entity charOffset="113-126" id="DDI-PubMed.15917146.s31.e1" text="flunitrazepam" /><pair ddi="false" e1="DDI-PubMed.15917146.s31.e0" e2="DDI-PubMed.15917146.s31.e0" /><pair ddi="false" e1="DDI-PubMed.15917146.s31.e0" e2="DDI-PubMed.15917146.s31.e1" /></sentence><sentence text=" The adverse interaction between flunitrazepam and buprenorphine cannot be explained by a pharmacokinetic drug-drug interaction during the distribution phase of buprenorphine"><entity charOffset="33-46" id="DDI-PubMed.15917146.s32.e0" text="flunitrazepam" /><entity charOffset="51-64" id="DDI-PubMed.15917146.s32.e1" text="buprenorphine" /><entity charOffset="161-174" id="DDI-PubMed.15917146.s32.e2" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.15917146.s32.e0" e2="DDI-PubMed.15917146.s32.e0" /><pair ddi="false" e1="DDI-PubMed.15917146.s32.e0" e2="DDI-PubMed.15917146.s32.e1" /><pair ddi="false" e1="DDI-PubMed.15917146.s32.e0" e2="DDI-PubMed.15917146.s32.e2" /><pair ddi="false" e1="DDI-PubMed.15917146.s32.e1" e2="DDI-PubMed.15917146.s32.e1" /><pair ddi="false" e1="DDI-PubMed.15917146.s32.e1" e2="DDI-PubMed.15917146.s32.e2" /></sentence><sentence text="" /></document>